Analytical Data
-
Gene name
CDK9-CCNT2
- Application
-
Alternative Names
C-2k; CDC2L4; PITALRE; TAK; CDC2-Related Kinase; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; Tat-associated kinase complex catalytic subunit
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P50750
-
Expression Region
Asp104~Phe315
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK9-CCNT2 is a crucial protein complex that plays a significant role in regulating transcriptional processes by phosphorylating the C-terminal domain of RNA polymerase II (Pol II). The cyclin-dependent kinase 9 (CDK9) is known for its involvement in the positive transcription elongation factor b (P-TEFb) complex, which enhances the transition of Pol II from a paused state to productive elongation during RNA synthesis. CCNT2, a cyclin type transcribed in response to various cellular signals, acts as a regulatory partner to CDK9, modulating its activity and stability. Research into the CDK9-CCNT2 complex has garnered attention due to its implications in various pathophysiological conditions, including cancer and viral infections, where dysregulation of transcriptional machinery can lead to uncontrolled cellular proliferation and survival. The study of recombinant CDK9-CCNT2 proteins enables the exploration of their biochemical properties, functional mechanisms, and interaction networks, providing insights into their roles in transcription regulation. Moreover, understanding the structure-function relationship of this complex could inform the development of novel therapeutic strategies targeting aberrant transcriptional control in diseases. Therefore, the research on CDK9-CCNT2 recombinant proteins is essential for advancing our knowledge of the transcriptional landscape and its implications in health and disease.
